Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (1489)	3/4/1999 8:01:00 AM
From: Anthony Wong	Read Replies (1) \| Respond to of 1722

Boehringer Ingelheim, Abbott Labs Form U.S. Marketing Pact Bloomberg News March 3, 1999, 5:37 a.m. ET Boehringer Ingelheim, Abbott Labs Form U.S. Marketing Pact Ingelheim, Germany, March 3 (Bloomberg) -- Boehringer Ingelheim Pharma KG, Europe's biggest privately held drugmaker, said it signed an agreement with the U.S.'s Abbott Laboratories to sell and promote its products in the U.S. Under the eight-year agreement, Abbott, the seventh-largest U.S. drugmaker, will sell Boehringer Ingelheim's Micardis (telmisartan) high blood-pressure medicine, which was introduced in the U.S. in January, and its Mobic (meloxicam) arthritis and rheumatism drug, which is used by more than a million patients in 70 countries. Financial details were not disclosed. Boehringer Ingelheim said the cooperation will expand the opportunities for both companies in the U.S., the world's largest pharmaceuticals market. It said more than 50 million Americans suffer from high blood pressure, and sales of drugs to treat this ailment total about $7.2 billion annually. The cooperation with Abbott gives Boehringer Ingelheim ''a strong marketing partner with an efficient service operation, which will give our products a good start in the U.S. market,'' said Rolf Krebs, chief of Boehringer Ingelheim's pharmaceutical unit. Abbott, of Abbott Park, Illinois, already has the co- marketing rights for meloxicam in Latin America, Central America, Mexico and the Caribbean. --Phyllis Carter in the Frankfurt newsroom (49-69) 92041-200/ph